19 annual accounts with figures on one time axis, 24 filings since 2002
peak of €1.5m in 2025
€1.5m▲ 3.4%
lowest -€285,130 in 2022
€23,980▼ 79.8%
peak of €859,416 in 2025
€859,416▲ 2.9%
€4.1m▲ 17.6%
peak of 11.4 FTE in 2024
10.6 FTE▼ 7.0%
Board9 names since 2001
4 directorsHidden nameVisible after signing in and 3 others
Owners
100%Name after signing inVisible after signing in
Documentsfilings and deeds
09-07-202622 days before the deadline
2025abbreviated format
Result from €118,944 to €23,980Hidden nameVisible after signing in (statutory auditor) and Hidden nameVisible after signing in (representative) appointed12-11Debts from €3.5m to €4.1mCash from €170 to €0
Hidden nameVisible after signing inseat since 14-01-2019
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 4,686 companies had the same profile as HEMOTECH BELUX has now. Each dot stands for 12 companies, two years later.
96.9%
were still trading
1.9%
stopped another way
1.1%
went bankrupt
Small
20 years or older
solvency 10 to 30%
a profit under 5% of the balance sheet
Test of the method
The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,686 companies, not a prediction for HEMOTECH BELUX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Hidden signalVisible after signing in
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Hidden signalVisible after signing in
Board and ownership
Name after signing inVisible after signing in
Director, Name hiddenVisible after signing in, since 01-07-2021
Hidden nameVisible after signing in
Director, Name after signing inVisible after signing in
Name hiddenVisible after signing in
Director, Hidden nameVisible after signing in
Name after signing inVisible after signing in
Director, since 22-10-2024
Name hiddenVisible after signing in
Auditor, Hidden nameVisible after signing in
Name after signing inVisible after signing in 100%score XXVisible after signing inequity €23.4m (2025) · annual accounts 2025 of Hidden nameVisible after signing in
Name after signing inVisible after signing in (statutory auditor) and Name hiddenVisible after signing in (representative) appointed
General meeting of 29-10-2025 · Gazette deed
Resignations & appointmentsHidden nameVisible after signing in resigns as director · Name after signing inVisible after signing in (director) and Name hiddenVisible after signing in (director) appointed · Hidden nameVisible after signing in and Name after signing inVisible after signing in act as permanent representatives · General meeting of 07-10-2024 · Gazette deed
Capital contribution of €400,000
General meeting of 20-12-2023 · Gazette deed
Capital contribution of €400,000
Contribution by Name hiddenVisible after signing in · Hidden nameVisible after signing in and Name after signing inVisible after signing in act as permanent representatives · General meeting of 22-12-2022 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as HEMOTECH BELUX: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €2.8m and €6m, founded between 1995 and 2003.
The company number of HEMOTECH BELUX is 0474.412.845. The VAT number is the same number with BE in front: BE 0474.412.845.
Where is HEMOTECH BELUX based?
The registered office is at Brouwerijstraat 14, 8680 Koekelare.Company details
What does HEMOTECH BELUX do?
According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of HEMOTECH BELUX?
HEMOTECH BELUX is a private limited company (BV).
When was HEMOTECH BELUX founded?
HEMOTECH BELUX was founded on 26-03-2001.
Is HEMOTECH BELUX still active?
Yes, HEMOTECH BELUX is an active enterprise in the KBO register.
How many employees does HEMOTECH BELUX have?
HEMOTECH BELUX had an average of 10.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does HEMOTECH BELUX fall under?
In its 2025 annual accounts, HEMOTECH BELUX states joint committee 200 (Auxiliary committee for white-collar workers).
What is the turnover of HEMOTECH BELUX?
The turnover in financial year 2025 is ≈ €6.0m. This figure is estimated from the gross margin of €1.5m and 96 comparable companies (NACE 46). It probably lies between €3.7m and €10.0m.
Is HEMOTECH BELUX profitable?
In financial year 2025, HEMOTECH BELUX made a profit of €23,980.
Where can I find the annual accounts of HEMOTECH BELUX?
HEMOTECH BELUX filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of HEMOTECH BELUX due?
HEMOTECH BELUX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline